These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17053813)

  • 1. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
    Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
    Lee SH; Bar-Haim E; Goldberger O; Reich-Zeliger S; Vadai E; Tzehoval E; Eisenbach L
    Immunol Lett; 2004 Feb; 91(2-3):119-26. PubMed ID: 15019279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
    Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
    Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
    Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
    Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
    Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis.
    Yakes FM; Wamil BD; Sun F; Yan HP; Carter CE; Hellerqvist CG
    Cancer Res; 2000 Oct; 60(20):5740-6. PubMed ID: 11059768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
    Dupont PJ; Warrens AN
    Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
    Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of CD95L expression on tumor rejection in mice.
    Igney FH; Behrens CK; Krammer PH
    Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand.
    Gregory MS; Saff RR; Marshak-Rothstein A; Ksander BR
    Cancer Res; 2007 Dec; 67(24):11951-8. PubMed ID: 18089826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD40 ligand in CD40-positive murine tumors activates transcription of the interleukin-23 subunit genes and produces antitumor responses.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2004; 24(5A):2713-6. PubMed ID: 15517876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Okada S; Tokuhisa T; Sakiyama S; Tagawa M
    J Immunol; 2002 Sep; 169(5):2241-5. PubMed ID: 12193688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.